Ranbaxy Reports Corrections At Dewas Plant To U.S. FDA; Hopes Import Restrictions Will Be Lifted Soon

MUMBAI - Part of Ranbaxy's troubles with its manufacturing units in India may be coming to an end in the next few months; the company has filed an exhaustive report with the U.S. FDA on corrections made at its manufacturing facilities at Dewas